CSPC Pharmaceutical Group Ltd.’s SYS-6011 has been cleared by China’s National Medical Products Administration (NMPA) to enter clinical trials in China for solid tumors.
At the Society for Immunotherapy of Cancer’s annual meeting, researchers from Tallac Therapeutics Inc. reported the discovery of TAC-003, a novel Toll-like receptor 9 (TLR9) agonist and Nectin-4-specific antibody conjugate, being developed as cancer immunotherapy candidate.
Scientists at the University of California San Francisco (UCSF) have designed a group of synthetic molecules that could prevent the rejection of allogeneic cell transplants. Their strategy consisted of activating the immune checkpoints of different populations of immune cells from the cell surface, but avoiding the cytotoxicity of natural killer (NK) cells and macrophages that would destroy the transplanted cells.
Shares of Werewolf Therapeutics Inc. (NASDAQ:HOWL) reflected enthusiasm on Wall Street for the prospect, albeit early stage, of systemically delivering a masked native interleukin-2 (IL-2) cytokine to cancer patients.
Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers.
Researchers from Medigene AG recently presented the discovery and preclinical evaluation of first-in-class, third-generation T-cell receptor T-cell (TCR-T) therapies, MDG-1015 and MDG-2011.
Chimeric Therapeutics Ltd. has received FDA clearance of its IND application for CHM-2101, a first-in-class CDH17 chimeric antigen receptor (CAR) T cell therapy for gastrointestinal (GI) cancers.
Sparx Biopharmaceutical Corp. has received FDA approval of its IND application for SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody drug candidate.
Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody (bsAb) designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity.
RSS
